Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 2186820)

2.

Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.

Qi CF, Nieroda C, De Filippi R, Greiner JW, Correale P, Schlom J, Tsang KY.

Immunol Lett. 1995 Jul-Aug;47(1-2):15-24.

PMID:
8537095
3.

Recombinant human macrophage colony-stimulating factor in nonhuman primates: selective expansion of a CD16+ monocyte subset with phenotypic similarity to primate natural killer cells.

Munn DH, Bree AG, Beall AC, Kaviani MD, Sabio H, Schaub RG, Alpaugh RK, Weiner LM, Goldman SJ.

Blood. 1996 Aug 15;88(4):1215-24. Erratum in: Blood 1996 Nov 15;88(10):4083.

5.

Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.

Schmid I, Baldwin GC, Jacobs EL, Isacescu V, Neagos N, Giorgi JV, Glaspy JA.

Cytometry. 1995 Jun 15;22(2):103-10.

PMID:
7587740
7.

Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.

Baldwin GC, Chung GY, Kaslander C, Esmail T, Reisfeld RA, Golde DW.

Br J Haematol. 1993 Apr;83(4):545-53.

PMID:
7686031
8.

Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity.

Mufson RA, Aghajanian J, Wong G, Woodhouse C, Morgan AC.

Cell Immunol. 1989 Mar;119(1):182-92.

PMID:
2646026
9.

Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.

Cole DJ, Sanda MG, Yang JC, Schwartzentruber DJ, Weber J, Ettinghausen SE, Pockaj BA, Kim HI, Levin RD, Pogrebniak HW, et al.

J Natl Cancer Inst. 1994 Jan 5;86(1):39-45.

PMID:
8271281
12.
13.

Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.

Liljefors M, Nilsson B, Mellstedt H, Frödin JE.

Cancer Immunol Immunother. 2008 Mar;57(3):379-88. Epub 2007 Aug 4.

PMID:
17676322
14.
15.
16.

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.

Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH.

J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):132-41.

PMID:
7804528
17.

Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.

Saleh MN, Khazaeli MB, Wheeler RH, Bucy RP, Liu T, Everson MP, Munn DH, Schlom J, LoBuglio AF.

Cancer Res. 1995 Oct 1;55(19):4339-46.

18.

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.

Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB.

Cancer. 1995 May 1;75(9):2251-7.

PMID:
7536122
19.

In vivo hematologic effects of recombinant human macrophage colony-stimulating factor.

Ulich TR, del Castillo J, Watson LR, Yin SM, Garnick MB.

Blood. 1990 Feb 15;75(4):846-50.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk